Skip to Content


Manufacturer of Controlled Substances; Notice of Withdrawal of Application

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 22566

By notice dated December 24, 2003, and published in the Federal Register on January 27, 2004 (68 FR 39437), Novartis Pharmaceuticals Corporation, Attn: Security Department, Building 103, Room 335, 59 Route 10, East Hanover, New Jersey 07936, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of Methylphenidate (1724), a basic class of controlled substance in Schedule II.

The firm planned to produce bulk product and finished dosage units for distribution to its customers.

By letter dated March 11, 2004, the firm stated that it is no longer engaged in the bulk manufacture of this controlled substance. The renewal application for Novartis Pharmaceuticals Corporation is hereby withdrawn.

Start Signature

Dated: April 1, 2004.

William J. Walker,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. 04-9328 Filed 4-23-04; 8:45 am]